Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies - PubMed
6 hours ago
- #alopecia areata
- #ritlecitinib
- #long-term efficacy
- Ritlecitinib demonstrated sustained efficacy over 3 years in patients with alopecia areata.
- At 3 years, 65.1% (observed) of patients achieved a SALT score ≤ 20, indicating significant hair regrowth.
- Most patients who responded at 1 year maintained their response through 3 years.
- Complete scalp hair regrowth (SALT score 0) was achieved by 31.2% (observed) of patients.
- Treatment response was associated with female sex, White race, and less severe baseline hair loss.
- No new safety signals were identified, supporting the long-term safety profile of ritlecitinib.